There is general agreement that most chemotherapy agents achieve only relatively low
concentrations in the normal central nervous system, that the blood-brain barrier is variably …

Several authors have proposed group sequential procedures to satisfy the ethicalneed in
clinical trials for interim analyses. We propose here an alternative procedure that offers a …

In the United States, lung cancer is now the leading cancer killer among men, and it will
soon be the leader among women. Most lung cancers are attributable to cigarette smoking …

In 103 patients with small-cell lung cancer, we compared four courses of standard doses of
Adriamycin (A)(Adria Laboratories, Columbus, Ohio), vincristine (V), and cyclophosphamide …

The somatic mutation model of cancer chemotherapy predicts that under certain conditions
some sequences of chemotherapy drug administration will be superior to others. Alternation …

The records of 227 patients with small cell lung cancer (SMCLC) treated between January
1974 and July 1978 in a series of randomized trials were reviewed to determine the …

Concepts of treatment for small cell carcinoma of the lung (SCCL) have evolved steadily
over the past decade. Initially, SCCL was viewed simply as a variant of" lung cancer," but it …

Over the past three decades, concepts concerning small cell lung cancer (SCLC) have
undergone major changes. In the 19505, SCLC was treated by surgery in the same manner …

BACKGROUND To assess whether the addition of cisplatin (100 mg/m2 administered
intravenously on Day 1) to CDE (cyclophosphamide [1000 mg/m2 on Day 1], doxorubicin [45 …

This study investigated the use of late dose intensification therapy (LDIT) with
cyclophosphamide (180 mg/kg) and VP 16 (1 g/m 2) plus autologous bone marrow rescue in …